Business & Industry

Teva Pharmaceutical Industries and Royalty Pharma have signed a funding agreement valued at up to $500 million to advance the development of TEV-408, an investigational therapy for autoimmune disorders, including vitiligo. The Teva, Royalty Pharma $500M deal would be...

Revvity, Inc. announced a collaboration with Eli Lilly and Company to broaden access to Lilly TuneLab by bringing the platform to the Revvity Signals ecosystem. The collaboration builds on Revvity’s recently launched Signals Xynthetica offering and aims to accelerate...

Daiichi Sankyo is now looking out for new horizons when it comes to its leukemia med Vanflyta, with Genesis Pharma signing to commercialize the drug across certain European countries. This exclusive license, as well as the supply agreement goes on to...

Shortly after going ahead and securing a partnership with Sanofi, InduPro is now linking up with Eli Lilly in its endeavors to discover novel cancer treatments through a pact that could as well be worth almost $950 million. InduPro is...

Nimbus Therapeutics has announced that it has entered into a multi-year research partnership and a $1.3 billion exclusive license agreement with Eli Lilly in order to develop oral treatments in obesity as well as other metabolic diseases. Lilly, which very...

Sanofi and Earendil Labs have announced a strategic collaboration effort that goes on to apply the discovery platform from Earendil across many of the Sanofi autoimmune and inflammatory disease programs. The two AI-powered research and development platforms from Earendil Labs concerning protein therapeutics go on...

Insilico Medicine has gone ahead with a multi-year research and development - R&D collaboration with Servier, of almost $888m, in order to develop and discover certain new oncology therapies. The partnership combines the AI drug discovery platforms of Insilico...